SCHEMBL26134380

SCHEMBL26134380

COc1cccc(F)c1C(=Cc1ccccc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 2/20 0.45
▸ KMT2A Q03164 5/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ PKM P14618 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ LMNA P02545 4/20 0.40
▸ PAX8 Q06710 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HTT P42858 3/20 0.40
▸ ATM Q13315 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ PTBP1 P26599 1/20 0.40
▸ STAT3 P40763 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26134377 1.00 KRAS (0.45) KRASKMT2AMEN1PKML3MBTL1
SCHEMBL29385894 0.75 HTR6 (0.42) KRASKMT2AMEN1PKML3MBTL1
SCHEMBL30822596 0.72 CA12 (0.74) KRASKMT2ALMNASMN1; SMN2HTT
SCHEMBL184045 0.72 CA12 (0.74) KRASKMT2ALMNASMN1; SMN2HTT
Hydrochloric Acid SCHEMBL30822580 0.71 CA12 (0.71) KRASKMT2ALMNASMN1; SMN2HTT
SCHEMBL5597547 0.71 CA12 (0.71) KRASKMT2ALMNASMN1; SMN2HTT
SCHEMBL28129617 0.71 CA12 (0.71) KRASKMT2ALMNASMN1; SMN2HTT
SCHEMBL28490326 0.70 ALDH1A1 (0.45) KMT2AMEN1PKML3MBTL1LMNA
SCHEMBL28490325 0.70 ALDH1A1 (0.45) KMT2AMEN1PKML3MBTL1LMNA
SCHEMBL28492017 0.70 ALDH1A1 (0.45) KMT2AMEN1PKML3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196975-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2023-10-12 — — WO disclosed
Send feedback